Danish Supreme Court upholds Spinraza decision, denies compensation claims
Doctors were right to deny treatment using Biogen’s drug Spinraza to children with muscular atrophy, the Danish Supreme Court has concluded.
by ritzau, translated by catherine brett
The Danish Medicines Council has previously concluded that Biogen’s muscular atrophy treatment Spinraza is not worth the money for a wider group of patients, as its high price is not in line with its effect.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
